Vaginal and Cervical Abnormalities, Including Clear-Cell Adenocarcinoma, Related to Prenatal Exposure to Stilbestrol*

Total Page:16

File Type:pdf, Size:1020Kb

Vaginal and Cervical Abnormalities, Including Clear-Cell Adenocarcinoma, Related to Prenatal Exposure to Stilbestrol* A n n a l s o p C l i n i c a l a n d L a b o r a t o r y S c i e n c e , V o l. 4, N o . 4 Copyright © 1974, Institute for Clinical Science Vaginal and Cervical Abnormalities, including Clear-Cell Adenocarcinoma, Related to Prenatal Exposure to Stilbestrol* ROBERT E. SCULLY, M.D., STANLEY J. ROBBOY, M.D., AND ARTHUR L. HERBST, M.D. Department of Pathology, Harvard Medical School, the James Homer Wright Pathology Laboratories and the Department of Gynecology, Massachusetts General Hospital (Vincent Memorial Hospital), and the Registry of Clear-Cell Adenocarcinoma of the Genital Tract in Young Females, Boston, Mass. 02114 ABSTRACT A variety of vaginal and cervical abnormalities have been encountered in the offspring of women who have taken stilbestrol or chemically related non­ steroidal estrogens during pregnancy. Cervical erosion has been noted most often, but vaginal adenosis has been proven by biopsy in over 30 percent, and transverse vaginal and cervical ridges have been seen in approximately 10 percent of the exposed population. Although the use of these drugs has been widespread during the last two decades, the Registry of Clear-Cell Adeno­ carcinoma of the Genital Tract in Young Females has been able to collect only 170 cases of vaginal and cervical cancers of this type from all over the world. It is important that cytologists and pathologists become familiar with the various non-neoplastic and neoplastic disorders related to these hor­ mones in order that additional epidemiologic, clinical and pathological infor­ mation be acquired without delay. Introduction sence of any similar cases in this age group In 1970 seven cases of clear-cell adeno­ in the records of that hospital during the carcinoma of the vagina that had devel­ half-century prior to 1966, as well as the oped in girls between the ages of 15 and failure to uncover more than a handful of 22 years were reported.13 These patients cases in a review of the world literature, had been seen at a single Massachusetts suggested the possibility that some sub­ hospital between 1966 and 1969. The ab­ stance recently introduced into the environ­ ment might have accounted for the sudden * This investigation was supported by grant outbreak of this very rare form of cancer. H01CA13139-02, National Cancer Institute grant In 1971 the results of an epidemiologic ET-52, American Cancer Society and a Junior Faculty Fellowship from the American Cancer study of these seven cases, in addition to Society (S.J.R.). an eighth case treated at a nearby hospital, ADENOCARCINOMA RELATED TO PRENATAL EXPOSURE TO ST1LBESTR0L 2 2 3 disclosed that seven of the eight girls were and Obstetrics, which designates a carci­ products of pregnancies during which their noma that involves both the vagina and mothers had been treated with diethystil- the cervix as cervical if it involves the ex­ bestrol.14 This drug had been administered ternal os.4 Accordingly, 70 of the 170 clear­ because of threatened abortion or prior cell adenocarcinomas were classified as cer­ pregnancy loss, beginning in the first tri­ vical even though it is probable that some mester. No such history was obtained in of these actually arose in the vagina and 32 carefully matched control cases. A con­ extended onto the cervix. The cervical can­ firmatory investigation was soon published cers had a highly significant association from New York State.11 Shortly after the with documented exposure to non-steroidal completion of the initial epidemiologic estrogens (52 percent), but a less impres­ study a Registry of Clear-Cell Adenocarci­ sive one than that of the vaginal carci­ noma of the Genital Tract in Young Fe­ nomas (73 percent).18 This difference is males* was established in order to cen­ not surprising in view of the fact that cer­ tralize information about this unusual form vical cancers of the clear-cell type in young of cancer in girls under the age of thirty females had been reported in the literature years, whether or not a history of drug much more frequently than their vaginal exposure can be elicited.1’2’3 counterparts in the prestilbestrol era.29 In November 1971, the Food and Drug The discovery of the association between Administration, recognizing the validity of these tumors and nonsteroidal estrogen ex­ the association between intrauterine expo­ posure in utero has led to a number of sure to stilbestrol or chemically related investigations in which asymptomatic ex­ non-steroidal estrogens and clear-cell ad­ posed girls have undergone screening ex­ enocarcinoma of the lower genital tract, aminations to exclude the presence of notified physicians in the United States carcinoma.16 These have revealed the ab­ that the administration of these drugs was normal presence of biopsy-verified gland­ contraindicated during pregnancy.6 ular epithelium in the vagina (vaginal By August 1973, the Registry had accu­ adenosis) in approximately 30 percent, mulated varying amounts of data on 170 tranverse vaginal or cervical fibrous ridges cases of clear-cell adenocarcinoma of the in about 10 percent and glandular epithel­ genital tract in young females.18 Investiga­ ium on the portio of the cervix in almost tion of the maternal history in 146 of these all of the cases. Although the last of these has disclosed an intrauterine exposure to three findings is occasionally encountered stilbestrol or the related drugs, hexestrol or in the form of congenital erosion in unex­ dienestrol, in 65 percent. A history of med­ posed girls in this age group, vaginal ad­ ication for the treatment of high-risk preg­ enosis and transverse ridges have proven nancy was obtained in an additional 12 to be extremely rare in girls whose mothers percent of the cases, but the specific drug did not receive these drugs during preg­ administered could not be identified. Thus, nancy. 78 percent of the patients were known to Now that gynecologists are examining have been exposed to some type of drug and biopsying the vaginas of young females during intrauterine life. exposed to non-steroidal estrogens with in­ The tumors in the Registry have been creasing frequency, pathologists are being classified according to the criteria of the confronted with diagnostic problems that International Federation of Gynecology were rarely encountered as recently as * Warren 275, 275 Charles Street, Boston, MA three years ago. The purpose of this paper 02114. is to discuss the pathology and clinical 224 SCULLY features of clear-cell adenocarcinomas of the vagina and cervix, vaginal adenosis and transverse ridges in this age group, based largely on the Registry cases and on screen­ ing examinations of the vagina in both live and autopsy populations. Observations C a r c i n o m a s On gross examination these tumors have been characteristically superficial and either polypoid, papillary or nodular, ranging in diameter from less than one to over 10 cm (figure l ).15 Occasionally, a small super­ ficial carcinoma has been removed almost entirely by biopsy so that no residual tumor F i g u r e 2. Clear-cell pattern of tumor resem­ bling renal cell carcinoma. (X300) is identifiable on gross examination of the resection specimen. A few of the tumors have been flat or ulcerated. Most of the vaginal carcinomas have been situated in the upper or middle thirds and have occupied primarily the anterior wall (figure 1). Almost all the cervical can­ cers have involved the exocervix, but many have affected the endocervix as well. In an occasional case, the latter has been the major site of involvement. On microscopical examination the tu­ mors have the features of clear-cell adeno­ carcinomas that have been encountered elsewhere in the female genital tract, par­ ticularly in the ovary. Characteristic pat­ terns are tubule and cyst formation, some­ times associated with a highly developed papillary architecture, and diffuse and in­ sular solid epithelial aggregates. The most common cell types are clear cells filled with glycogen, resembling those of the renal cell F i g u r e 1. Uterus and vagina opened along left lateral margin. Polypoid carcinoma is present on carcinoma (figure 2 ), and hobnail cells anterior wall. Patch of adenosis on posterior wall lining the tubules and cysts and character­ and at margin of tumor. The cervical portio is extensively eroded. Reprinted with the permission ized by bulbous nuclei that protrude into of Cancer 25:745-757, 1970. the lumens beyond the apparent cytoplas- ADENOCARCINOMA RELATED TO PRENATAL EXPOSURE TO STILBESTROL 225 more deeply than the Stage I vaginal car­ cinomas, many of which have invaded the wall less than two mm.15 Examination of cytologic smears has re­ vealed the presence of malignant cells in most of the cases that have been reviewed, although many of the smears had been ob­ tained only after clinical visualization of the tumor.20 Although a positive smear was occasionally the first clue to the diagnosis, negative results were sufficiently frequent to invalidate cytology as a uniformly reli­ able method of detection. False negative smears may have been related to an ab­ sence of tumor cells or a high degree of differentiation, or to the presence of numer­ ous inflammatory cells, which tend to ob­ scure the neoplastic elements. The tumor cells occur both singly and in clumps and F i g u r e 3. Tubules lined by hobnail cells. (X180) in general resemble endocervical cells, par­ ticularly when well differentiated. Typ­ ically the nuclei are large and contain mic limits of the cells (figure 3). The hob­ nail cells of the tubules are generally prom­ prominent nucleoli (figure 5), but in some inent, while those lining cysts, which are more often present in the deeper portions of the tumor, are sometimes so flattened that they appear innocuous on superficial examination (figure 4).
Recommended publications
  • Pembrolizumab in Vaginal and Vulvar Squamous Cell Carcinoma: a Case Series from a Phase II Basket Trial Jefrey A
    www.nature.com/scientificreports OPEN Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial Jefrey A. How 1, Amir A. Jazaeri 1, Pamela T. Soliman1, Nicole D. Fleming1, Jing Gong2, Sarina A. Piha‑Paul2, Filip Janku 2, Bettzy Stephen 2 & Aung Naing 2* Vaginal and vulvar squamous cell carcinoma (SCC) are rare tumors that can be challenging to treat in the recurrent or metastatic setting. We present a case series of patients with vaginal or vulvar SCC who were treated with single‑agent pembrolizumab as part of a phase II basket clinical trial to evaluate efcacy and safety. Two cases of recurrent and metastatic vaginal SCC, with multiple prior lines of systemic chemotherapy and radiation, received pembrolizumab. One patient had signifcant reduction (81%) in target tumor lesions prior to treatment discontinuation at cycle 10 following confrmed progression of disease with new metastatic lesions (stable disease by irRECIST criteria). In contrast, the other patient with vaginal SCC discontinued treatment after cycle 3 due to disease progression. Both patients had PD‑L1 positive vaginal tumors and tolerated treatment well. One case of recurrent vulvar SCC with multiple surgical resections and prior progression on systemic carboplatin had a 30% reduction in her target tumor lesions following pembrolizumab treatment with a PD‑L1 positive tumor. Treatment was discontinued for grade 3 mucositis after cycle 5. Pembrolizumab may provide some clinical beneft to some patients with vaginal or vulvar SCC and is overall safe to utilize in this population. Future studies are needed to evaluate the efcacy of pembrolizumab in these rare tumor types and to identify predictive biomarkers of response.
    [Show full text]
  • Gynecological Malignancies in Aminu Kano Teaching Hospital Kano: a 3 Year Review
    Original Article Gynecological malignancies in Aminu Kano Teaching Hospital Kano: A 3 year review IA Yakasai, EA Ugwa, J Otubu Department of Obstetrics and Gynecology, Aminu Kano Teaching Hospital, Kano and Center for Reproductive Health Research, Abuja, Nigeria Abstract Objective: To study the pattern of gynecological malignancies in Aminu Kano Teaching Hospital. Materials and Methods: This was a retrospective observational study carried out in the Gynecology Department of Aminu Kano Teaching Hospital (AKTH), Kano, Nigeria between October 2008 and September 2011. Case notes of all patients seen with gynecological cancers were studied to determine the pattern, age and parity distribution. Results: A total of 2339 women were seen during the study period, while 249 were found to have gynecological malignancy. Therefore the proportion of gynecological malignancies was 10.7%. Out of the 249 patients with gynecological malignancies, most (48.6%) had cervical cancer, followed by ovarian cancer (30.5%), endometrial cancer (11.25%) and the least was choriocarcinoma (9.24%). The mean age for cervical carcinoma patients (46.25 ± 4.99 years) was higher than that of choriocarcinoma (29 ± 14.5 years) but lower than ovarian (57 ± 4.5years) and endometrial (62.4 ± 8.3 years) cancers. However, the mean parity for cervical cancer (7.0 ± 3) was higher than those of ovarian cancer (3 ± 3), choriocarcinoma (3.5 ± 4) and endometrial cancer (4 ± 3). The mean age at menarche for women with cervical cancer (14.5 ± 0.71 years) was lower than for those with choriocarcinoma (15 ± 0 years), ovarian (15.5 ± 2.1 years) and endometrial (16 ± 0 years) cancers.
    [Show full text]
  • Clinical Radiation Oncology Review
    Clinical Radiation Oncology Review Daniel M. Trifiletti University of Virginia Disclaimer: The following is meant to serve as a brief review of information in preparation for board examinations in Radiation Oncology and allow for an open-access, printable, updatable resource for trainees. Recommendations are briefly summarized, vary by institution, and there may be errors. NCCN guidelines are taken from 2014 and may be out-dated. This should be taken into consideration when reading. 1 Table of Contents 1) Pediatrics 6) Gastrointestinal a) Rhabdomyosarcoma a) Esophageal Cancer b) Ewings Sarcoma b) Gastric Cancer c) Wilms Tumor c) Pancreatic Cancer d) Neuroblastoma d) Hepatocellular Carcinoma e) Retinoblastoma e) Colorectal cancer f) Medulloblastoma f) Anal Cancer g) Epndymoma h) Germ cell, Non-Germ cell tumors, Pineal tumors 7) Genitourinary i) Craniopharyngioma a) Prostate Cancer j) Brainstem Glioma i) Low Risk Prostate Cancer & Brachytherapy ii) Intermediate/High Risk Prostate Cancer 2) Central Nervous System iii) Adjuvant/Salvage & Metastatic Prostate Cancer a) Low Grade Glioma b) Bladder Cancer b) High Grade Glioma c) Renal Cell Cancer c) Primary CNS lymphoma d) Urethral Cancer d) Meningioma e) Testicular Cancer e) Pituitary Tumor f) Penile Cancer 3) Head and Neck 8) Gynecologic a) Ocular Melanoma a) Cervical Cancer b) Nasopharyngeal Cancer b) Endometrial Cancer c) Paranasal Sinus Cancer c) Uterine Sarcoma d) Oral Cavity Cancer d) Vulvar Cancer e) Oropharyngeal Cancer e) Vaginal Cancer f) Salivary Gland Cancer f) Ovarian Cancer & Fallopian
    [Show full text]
  • Ovarian Insufficiency and CTNNB1 Mutations Drive Malignant Transformation of Endometrial Hyperplasia with Altered PTEN/PI3K Activities
    Ovarian insufficiency and CTNNB1 mutations drive malignant transformation of endometrial hyperplasia with altered PTEN/PI3K activities Jumpei Terakawaa,b,1,2, Vanida Ann Sernaa,b,1, Makoto Mark Taketoc, Takiko Daikokud, Adrian A. Suarezb,e, and Takeshi Kuritaa,b,3 aDepartment of Cancer Biology and Genetics, Ohio State University, Columbus, OH 43210; bThe Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210; cDivision of Experimental Therapeutics, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, 606-8506 Kyoto, Japan; dDivision of Transgenic Animal Science, Advanced Science Research Center, Kanazawa University, 920-8640 Kanazawa, Japan; and eDepartment of Pathology, Ohio State University, Columbus, OH 43210 Edited by Patricia K. Donahoe, Pediatric Surgical Research Laboratories, Massachusetts General Hospital, Department of Surgery, Harvard Medical School, Boston, MA, and approved January 23, 2019 (received for review August 28, 2018) Endometrioid endometrial carcinomas (EECs) carry multiple driver PI3K (5). However, PTEN and PI3K (PIK3CA or PIK3R1)mu- mutations even when they are low grade. However, the biological tations co-occurred in 67% (59/88) of CL-EECs. This observation significance of these concurrent mutations is unknown. We explored questions the widely accepted concept that the loss of PTEN and the interactions among three signature EEC mutations: loss-of- activation of PI3K have synonymous effects on cellular physiology, as function (LOF) mutations in PTEN, gain-of-function (GOF) mutations they catalyze opposite reactions: PI3K converts phosphatidylinositol of phosphoinositide 3-kinase (PI3K), and CTNNB1 exon 3 mutations, (4,5)-biphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate utilizing in vivo mutagenesis of the mouse uterine epithelium.
    [Show full text]
  • Vaginal Cancer, Risk Factors, and Prevention Risk Factors for Vaginal
    cancer.org | 1.800.227.2345 Vaginal Cancer, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors for vaginal cancer. ● Risk Factors for Vaginal Cancer ● What Causes Vaginal Cancer? Prevention There's no way to completely prevent cancer. But there are things you can do that might help lower your risk. Learn more here. ● Can Vaginal Cancer Be Prevented? Risk Factors for Vaginal Cancer A risk factor is anything that affects your chance of getting a disease such as cancer. Different cancers have different risk factors. Some risk factors, like smoking, can be changed. Others, like a person’s age or family history, can’t be changed. But having a risk factor, or even many, does not mean that you will get the disease. And 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 some people who get the disease may not have any known risk factors. Scientists have found that certain risk factors make a woman more likely to develop vaginal cancer. But many women with vaginal cancer don’t have any clear risk factors. And even if a woman with vaginal cancer has one or more risk factors, it’s impossible to know for sure how much that risk factor contributed to causing the cancer. Age Squamous cell cancer of the vagina occurs mainly in older women. It can happen at any age, but few cases are found in women younger than 40. Almost half of cases occur in women who are 70 years old or older.
    [Show full text]
  • After Endometrial Cancer Treatment Living As a Cancer Survivor
    cancer.org | 1.800.227.2345 After Endometrial Cancer Treatment Living as a Cancer Survivor For many people, cancer treatment leads to questions about the next steps as a survivor or about the chances of the cancer coming back. ● Living as an Endometrial Cancer Survivor Cancer Concerns After Treatment Treatment may remove or destroy the cancer, but it's very common to worry about the risk of developing another cancer. ● Second Cancers After Endometrial Cancer Living as an Endometrial Cancer Survivor For many women with endometrial cancer, treatment may remove or destroy the cancer. Completing treatment can be both stressful and exciting. You may be relieved to finish treatment, but find it hard not to worry about cancer coming back. (When cancer comes back after treatment, it's called recurrence1.) This is a very common concern in people who have had cancer. 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 For other women, this cancer may never go away completely2. They may get regular treatments with chemotherapy, radiation, or other therapies to try to help keep the cancer in check. Learning to live with cancer that doesn't go away can be difficult and very stressful. Follow-up care When treatment ends, your doctors will still want to watch you closely. It's very important to go to all of your follow-up appointments. During these visits, your doctors will ask questions about any problems you may have and may do physical exams, blood tests, or x-rays and scans to look for signs of cancer or treatment side effects3.
    [Show full text]
  • Sex Determination and Differentiation
    The new england journal of medicine review article mechanisms of disease Sex Determination and Differentiation David T. MacLaughlin, Ph.D., and Patricia K. Donahoe, M.D. ex determination, which depends on the sex-chromosome com- From the Pediatric Surgical Research Lab- plement of the embryo, is established by multiple molecular events that direct the oratories and the Pediatric Surgical Servic- s es, Massachusetts General Hospital and development of germ cells, their migration to the urogenital ridge, and the forma- Harvard Medical School, Boston. Address tion of either a testis, in the presence of the Y chromosome (46,XY), or an ovary in the reprint requests to Dr. MacLaughlin or Dr. absence of the Y chromosome and the presence of a second X chromosome (46,XX). Donahoe at the Pediatric Surgical Research Laboratories, Massachusetts General Hos- Sex determination sets the stage for sex differentiation, the sex-specific response of tis- pital, Boston, MA 02114, or at maclaughlin@ sues to hormones produced by the gonads after they have differentiated in a male or fe- helix.mgh.harvard.edu or donahoe.patricia male pattern. A number of genes have been discovered that contribute both early and late @mgh.harvard.edu. to the process of sex determination and differentiation. In many cases our knowledge has N Engl J Med 2004;350:367-78. derived from studies of either spontaneous or engineered mouse mutations that cause Copyright © 2004 Massachusetts Medical Society. phenotypes similar to those in humans. We will examine how mutations in these genes cause important clinical syndromes (Table 1 and Fig. 1) and discuss clinical entities that continue to elude classification at the molecular level.
    [Show full text]
  • Case Report a Report of Two Cases of Age-Related Changes in Cervical Morphology in Postmenopausal Women with Vaginal Adenosis
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Crossref Hindawi Case Reports in Obstetrics and Gynecology Volume 2017, Article ID 9523853, 4 pages https://doi.org/10.1155/2017/9523853 Case Report A Report of Two Cases of Age-Related Changes in Cervical Morphology in Postmenopausal Women with Vaginal Adenosis Marguerite B. Vigliani Alpert Medical School at Brown University, Providence, RI, USA Correspondence should be addressed to Marguerite B. Vigliani; [email protected] Received 28 October 2016; Accepted 18 December 2016; Published 2 January 2017 Academic Editor: John P. Geisler Copyright © 2017 Marguerite B. Vigliani. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This paper presents two cases of women who had extensive vaginal adenosis from prenatal DES exposure, extending almost halfway down the vaginal canal. Both women were followed for decades with annual exams and Pap smears until after menopause. Clinical examination in both cases initially showed an absent pars vaginalis of the cervix, vaginal adenosis, and shallowness of the fornices. Several decades of annual exams showed these stigmata of DES exposure gradually disappear as the upper vagina progressively contracted. After menopause the upper vagina in both cases transformed into what appeared to be a normal cervix with all adenosis involuted into a normal endocervical canal. A timeline was created to show the morphological changes that were observed over time. This timeline illustrates how severe vaginal stenosis above the level of the squamocolumnar junction developed in middle age and was followed in the postmenopause by fusion of the upper vaginal walls in the midline resulting in the appearance of a normal, but prolapsed, cervix.
    [Show full text]
  • Vaginal Intraepithelial Neoplasia: a Therapeutical Dilemma
    ANTICANCER RESEARCH 33: 29-38 (2013) Vaginal Intraepithelial Neoplasia: A Therapeutical Dilemma ANTONIO FREGA1*, FRANCESCO SOPRACORDEVOLE2*, CHIARA ASSORGI1, DANILA LOMBARDI1, VITALIANA DE SANCTIS3, ANGELICA CATALANO1, ELEONORA MATTEUCCI1, GIUSI NATALIA MILAZZO1, ENZO RICCIARDI1 and MASSIMO MOSCARINI1 Departments of 1Gynecological, Obstetric and Urological Sciences, and 3Radiotherapy, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy; 2Department of Gynaecological Oncology, National Cancer Institute, Aviano, Italy Abstract. Vaginal intraepithelial neoplasia (VaIN) thirds of the epithelium. Carcinoma in situ, which involves represents a rare and asymptomatic pre-neoplastic lesion. Its the full thickness of the epithelium, is included in VaIN 3. natural history and potential evolution into invasive cancer The natural history of VaIN is thought to be similar to that of are uncertain. VaIN can occur alone or as a synchronous or cervical intraepithelial neoplasia (CIN), although there is metachronous lesion with cervical and vulvar HPV-related little information regarding this. The management of this intra epithelial or invasive neoplasia. Its association with intraepithelial neoplasia should be tailored according to the cervical intraepithelial neoplasia is found in 65% of cases, patient. After early treatment, VaIN frequently regresses, but with vulvar intraepithelial neoplasia in 10% of cases, while patients require careful long-term monitoring after initial for others, the association with concomitant cervical or therapy due to high risk of recurrence and progression. The vulvar intraepithelial neoplasias is found in 30-80% of cases. purpose of this review is to identify the best management of VaIN is often asymptomatic and its diagnosis is suspected in VaIN basing therapy on patients’ characteristics. cases of abnormal cytology, followed by colposcopy and colposcopically-guided biopsy of suspicious areas.
    [Show full text]
  • Vaginal Cancer
    VAGINAL CANCER The Facts Vaginal cancer is a rare cancer of the female reproductive system. Around 15 women are diagnosed with it every year in Ireland. The vagina is part of the female reproductive system. It is a muscular tube about 10cm long. It is the passage between the opening of the womb (cervix) and the vulva. The vagina is the opening that allows blood to drain out each month during your menstrual period. The walls of the vagina are normally in a relaxed state. The vagina opens and expands during sexual intercourse and it stretches during childbirth to allow the baby to come out. Symptoms It’s rare to have symptoms if you have pre-cancerous cell changes in the lining of the vagina, called vaginal intraepithelial neoplasia (VAIN). As many as 20 in 100 women (20%) diagnosed with vaginal cancer don’t have symptoms at all. Your doctor may pick up signs of VAIN or very early vaginal cancer during routine cervical screening. However, around 80 out of 100 women (80%) with vaginal cancer have one or more symptoms. These can include: • bleeding in between periods or after the menopause • bleeding after sex • vaginal discharge that smells or is blood stained • pain during sexual intercourse • a lump or growth in the vagina that you or your doctor can feel • a vaginal itch that won’t go away Remember that many of these symptoms can also be caused by other conditions, such as infection. VAGINAL CANCER Risk Factors Although the exact cause of vaginal cancer isn't known, certain factors appear to increase your risk of the disease, including: • Increasing age: The risk of vaginal cancer increases with age, though it can occur at any age.
    [Show full text]
  • CLINICAL GUIDELINES Oncology Imaging Policy Version 3.0.2019 Effective August 1, 2019
    CLINICAL GUIDELINES Oncology Imaging Policy Version 3.0.2019 Effective August 1, 2019 eviCore healthcare Clinical Decision Support Tool Diagnostic Strategies: This tool addresses common symptoms and symptom complexes. Imaging requests for individuals with atypical symptoms or clinical presentations that are not specifically addressed will require physician review. Consultation with the referring physician, specialist and/or individual’s Primary Care Physician (PCP) may provide additional insight. CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright 2016 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein. © 2019 eviCore healthcare. All rights reserved. Imaging Guidelines V3.0.2019 Oncology Imaging Guidelines Abbreviations for Oncology Guidelines 3 ONC-1: General Guidelines 5 ONC-2: Primary Central Nervous System Tumors 18 ONC-3: Squamous Cell Carcinomas of the Head and Neck 32 ONC-4: Salivary Gland Cancers 39 ONC-5: Melanomas and Other Skin Cancers 46 ONC-6: Thyroid Cancer 59 ONC-7: Small Cell Lung Cancer 67 ONC-8: Non-Small Cell Lung Cancer 72 ONC-9: Esophageal Cancer 80 ONC-10: Other Thoracic Tumors 87 ONC-11: Breast Cancer 97 ONC-12: Sarcomas – Bone, Soft Tissue
    [Show full text]
  • Gynecological Malignancies in Pediatric and Adolescent Group: a Ten Year Experience in a National Cancer Center of Nepal
    dd] fl] /on Sof fnf G;/ O] / c f : =s k L t k f = n L a B L . P A . T K I O P I S Nepalese Journal of Cancer (NJC) R O A 2049BS/1992AD H BPKMCH LA BPKMCH,NEPAL R M CE EMORIAL CAN Original Article Gynecological malignancies in pediatric and adolescent group: a ten year experience in a national cancer center of Nepal. Sharma KS1, Pariyar J2,Misra D3, Mehta S3, Panthee s4 1Consultant, Department of medical oncology, Pediatric Oncology Unit, B. P. Koirala Memorial Cancer Hospital, Bharatpur, Nepal 2Consultant, Gynecological oncology Unit, Civil Service hospital, Kathmandu, Nepal 3Medical officer, Department of medical oncology, Pediatric Oncology Unit, B. P. Koirala Memorial Cancer Hospital, Bharatpur, Nepal 4Senior Nursing officer ,Department of Nursing, Hospice and Palliative care Unit, B. P. Koirala Memorial Cancer Hospital, Bharatpur, Nepal ABSTRACT Introduction: Gynecological malignancies in pediatric and adolescent group are common. Germ cell tumors and gestational trophoblastic neoplasia are the most frequently found malignancies which are highly chemosensitive. With prompt and appropriate treatment higher cure rate is attainable in such malignancies even in resource constraints country like Nepal. Objective: To study the clinicopathological profile and treatment outcome of gynecological malignancies among pediatric and adolescent group seeking treatment at B.P. Koirala Memorial Cancer Hospital (BPKMCH), Nepal. Methodology: Descriptive study was done at BPKMCH Nepal. All available case records of pediatric and adolescent girls diagnosed to have gynecological malignancies from 2002 to 2011 were collected and analyzed in terms of age, clinical features, malignancy types, treatment modalities and outcome. Results: Total 60 girls were eligible for the study.
    [Show full text]